subscribeSubscribe
ASCO: Merck KGaA`s Bavencio combo misses survival mark in RCC

ASCO: Merck KGaA`s Bavencio combo misses survival mark in RCC
Angus Liu FIERCE PHARMA
23 May 2024
Share Share
Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo

Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo
BUSINESSWIRE
15 May 2024
Share Share
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line

Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line
BUSINESSWIRE
22 Jan 2024
Share Share
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights

Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
REUTERS
13 Dec 2023
Share Share
EMD Serono`s Biologic Bavencio (Avelumab) Receives Approval in the U.S.

EMD Serono`s Biologic Bavencio (Avelumab) Receives Approval in the U.S.
FDA
06 Sep 2023
Share Share
Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC

Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC
ONCLIVE
18 Aug 2023
Share Share
Post-Hoc Analysis Confirms Safety of Maintenance Avelumab

Post-Hoc Analysis Confirms Safety of Maintenance Avelumab
Ashling Wahner ONCLIVE
03 Jul 2023
Share Share
Positive Results from Interim Analysis of `GEN-001` Plus avelumab PII Trial

Positive Results from Interim Analysis of `GEN-001` Plus avelumab PII Trial
PR NEWSWIRE
19 May 2023
Share Share
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends

Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Paul Schloesser ENDPTS
28 Mar 2023
Share Share
Merck KGaA Strengthens Oncology Franchise by Securing Rights to BAVENCIO

Merck KGaA Strengthens Oncology Franchise by Securing Rights to BAVENCIO
BUSINESSWIRE
27 Mar 2023
Share Share